drugset / Trial / NCT00624702

Tolerability of Indacaterol Salts (Maleate, Xinafoate and Acetate) in Comparison to Placebo in Patients With Mild to Moderate Persistent Asthma

NCT00624702

Phase 1 Completed 98 enrolled Novartis
RandomizedCrossoverQuadruple-blindTreatment

Summary

This study will explore information on whether changing the salt formulation of indacaterol affects the incidence of post-inhalation cough.

Timeline

Start
2008-02
Primary completion
2008-09
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Indacaterol Other / unclassified 400 ug Inhaled

Indications